Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Conference Call March 27, 2024 8:30 AM ET
Company Participants
Jim Caruso - President and CEO
Andrei Shustov - SVP, Medical
Jarrod Longcor - COO
Shane Lea - Chief Commercial Officer
Chad Kolean - CFO
Conference Call Participants
Jonathan Aschoff - ROTH MKM
Jeff Jones - Oppenheimer
Operator
Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today's call is being recorded.
Before we begin, I would like to remind everyone that statements made during this call relating to Cellectar’s expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could differ materially believe from those forecasts due to the impact of many factors beyond the control of Cellectar.
The company assumes no obligation to update supplements, or supplements any further any forward-looking statements whether as a result of new information, future events, or otherwise. Participants are directed to the cautionary notes set forth in today's press release, which is available on the Investor Relations portion of the company's website, as well as risk factors set forth in Cellectar’s annual reports filed with the SEC for factors that could cause actual results to differ materially from those anticipated in forward-looking statements.
At this time, I would like to turn the call over to Jim Caruso, President and Chief Executive Officer of Cellectar. Mr. Caruso, please go ahead.
Jim Caruso
Thank you, Mark. And good morning, everyone. It is my pleasure to be here with you to report our year-end results and provide a corporate update. With me today are Dr. Andrei Shustov, Senior Vice President, Medical; Jarrod Longcor, Chief Operating Officer; Shane Lea, Chief Commercial Officer; and Chad Kolean, our Chief Financial Officer.
I will begin today with a brief overview of the meaningful accomplishments the company has achieved these past 12 months. I will then review our WM plans after which I will turn the call over to our team for a more in-depth update. You will first hear from Dr. Shustov. He will provide a review of our successful WM trial results and discuss Iopofosine I-131 clinical development programming.
Regarding PWM pivotal study, I am pleased to report that we remain on track for Q2 announcement of our updated top-line data from our CLOVER-WaM study. Jarrod will provide an update on our regulatory plans and NDA filing. Shane will review our commercial readiness plans and announced the hiring of additional commercial talent to support the potential launch of WM. Followed by Jarrod, providing an update on our lead alpha-emitter, phospholipid radio conjugate or PRC and briefly discuss why our alpha-emitters provide unique mechanism of action qualities which differentiate our PRCs from existing alpha-emitters in development.